UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): January 14, 2011
GENEREX
BIOTECHNOLOGY CORPORATION
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-29169
|
|
98-0178636
|
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer Identification No.)
|
|
33
Harbour Square, Suite 202, Toronto, Ontario Canada
|
|
M5J
2G2
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (416) 364-2551
N/A
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment ofCertain Officers;
Compensatory Arrangement of Certain Officers.
On
January 14, 2011, Anna E. Gluskin resigned as a director of Generex
Biotechnology Corporation (the “Company”) pursuant to the agreement that Ms.
Gluskin reached with the Company with respect to her termination as President
and Chief Executive Officer of the Company on September 29, 2010. Ms.
Gluskin also resigned as a director and as an officer of each of the following
subsidiaries of the Company effective as of January 14, 2011: Generex
Pharmaceuticals Inc., Antigen Express, Inc., Generex Bermuda, Inc., Generex
Pharmaceuticals (USA) LLC, SIA “Generex Biotechnology BALTIC”, Generex
Biotechnology Limited, and Generex Marketing & Distribution
Inc.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
GENEREX
BIOTECHNOLOGY CORPORATION.
|
||||||
|
Date:
January 21, 2011
|
/s/ Mark A. Fletcher
|
|||||
|
Mark
A. Fletcher
Interim
Chief Executive Officer and President
|
||||||
|
/s/ John P. Barratt
|
||||||
|
John
P. Barratt
|
||||||
|
Chairman
|
||||||